Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 503 results for "Tecfidera"

Human medicines European public assessment report (EPAR): Te...

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ... European Medicines Agency, 2 weeks ago

9 images for Tecfidera

Bidness Etc, 1 day ago
Motley Fool, 2 months ago
European Pharmaceutical Review, 2 months ago, 2 months ago
Nasdaq, 2 months ago
Nasdaq, 2 months ago
Nasdaq, 2 months ago
Nasdaq, 2 months ago, 2 months ago

Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16

Strong Product Portfolio Drove Biogen's 1Q16 Profit Margins ( Continued from Prior Part ) Tecfidera performance By the end of 1Q16, Biogen's (BIIB) leading multiple sclerosis (or MS) drug, Tecfidera, had treated about 190,000 multiple ...
 Yahoo! Finance UK and Ireland2 months ago Biogen Witnessed Strong Growth in Net Profit Margins in 1Q16  Yahoo! Finance UK and Ireland1 month ago Tysabri Reports Strong Patient Growth in 1Q16  Yahoo! Finance UK and Ireland1 month ago Biogen's Hemophilia Drugs Continue to Capture Market Share in 1Q16  Yahoo! Finance UK and Ireland1 month ago
European Pharmaceutical Review

TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness

-- More than Half of Newly Diagnosed MS Patients Taking TECFIDERA Remained Free of Relapse and Disability Progression Over Six Years -- -- New Analyses Show TECFIDERA Associated with Significantly Lower ARR Relative to Glatiramer Acetate, ...
 Bloomberg2 months ago Tecfidera demonstrates sustained efficacy in RRMS studies  European Pharmaceutical Review2 months ago TECFIDERA data confirm strong and sustained efficacy in newly diagnosed MS patients and real-world effectiveness  Medical News Today2 months ago Biogen Reports TECFIDERA Data Confirms Strong, Sustained Efficacy in Newly-Diagnosed MS Patients  Morningstar.com2 months ago

New Data at CMSC Assess Real-World Impact of Rebif® (interferon beta-1a) in People with Relapsing MS

- Data compare Rebif vs. Tecfidera® and Aubagio® in the first year of treatment - Assessments include likelihood of relapse, medical costs and outpatient management resources needs 09:00 ET from EMD Serono ROCKLAND, Mass., June 2, 2016 ...
 PR Newswire3 weeks ago EMD Serono Release: New Data At Assess Real-World Impact Of Rebif (Interferon Beta-1a) In People With Relapsing MS  BioSpace3 weeks ago

Biogen Q1 profits rise boosted by Tecfidera sales

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter profit driven by sales ofmultiple-sclerosis drug Tecfidera. The biotech firm reported profit of $970.9 million, or $4.43 a ...
 Pharmafile2 months ago Biogen Profit Climbs On Higher Sales of Multiple-Sclerosis Drug  Nasdaq2 months ago Tecfidera sales growth fuels Biogen's rise in first-quarter revenue, profit  FirstWord Pharma2 months ago BIOGEN : Profit Climbs, Helped by Stronger Sales of Tecfidera  4 Traders2 months ago
Reuters UK

Onset of Parkinson's Disease May Be Slowed by Metabolite in MS Drug, Mouse Study Shows

Dimethylfumarate (Tecfidera), a drug used to harness multiple sclerosis symptoms, generates a metabolite that could be used in Parkinson's patients to improve defenses against oxidative damage. The drug actson Nrf2, a molecule that has frequently ...
 Parkinson'sNewsToday.com1 week ago Biogen's MS Drug Fails to Meet Goals in Study  Bioscience Technology Online2 weeks ago Biogen's MS drug misses main goal in mid-stage study  Yahoo! India2 weeks ago UPDATE 2-Biogens MS drug misses main goal in mid-stage study  Reuters UK2 weeks ago

Fingolimod Easier to Swallow Than Dimethyl Fumarate?

Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis
 RxList2 months ago Real-world data favor dimethyl fumarate, fingolimod for MS  PM 3601 week ago

February 2016 Tecfidera Label Change Adds Information About PML Risks

There seems to have been more Tecfidera progressive multifocal leukoencephalopathy (PML) cases reported in the past year or so. And it seems that lymphonpenia possibly induced by Tecfidera might have a role to play in those additional PML cases. ...
 DrugInjuryLaw.com1 month ago A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice  Drug Injury Watch1 month ago

Biogen's controversial Tecfidera ad is about to meet its end

Biogen's DTC ad for multiple sclerosis pill Tecfidera has garnered its fair share of criticism from patients who say it's unrealistic. But that didn't stop the TV commercial from getting the job done, the company says--and now that it has, it's on ...
 FiercePharma1 month ago Biogen's 'active woman' Tecfidera ad will go off air soon  BioPharma Dive1 month ago

TECFIDERA® data highlights benefit of early treatment in relapsing-remitting multiple sclerosis

Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with ...
 Hospital Pharmacy Europe1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less